CSU.TO 67.76NFLX 0.62LLY 6.15EVR -7.36MSFT -11.38DAL -0.09JPM 1.48
Daily Stock Opinions and Ratings
Stockchase Opinions

David BurrowsVasoginVAS.TODON'T BUYDec 16, 2003

They are risk model on bile tax turned negative a couple of months ago so they sold their holdings. Well-run and has an interesting product. They are in the process of being listed in the US. Wait for some strength in that sector.
David BurrowsDavid Burrows
No
Unlock Rating
$7.47

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist
Track your Stocks in your Watch List

You might be interested:

DON'T BUY

Vasogin(VAS.TO)

Apr 19, 2007
When a biotech finds the right thing, the stock can jump like crazy. This company just had a 1 for 10 reverse split. 90% of companies that do a reverse split are still down one year later.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$4.50

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Vasogin(VAS.TO)

Feb 21, 2007
This one is past the point of no return. Speculative.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$0.43

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Vasogin(VAS.TO)

Jan 17, 2005

(Top Short Sept 8/04. Sold in low $5's so he's ahead about 19%.)

Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$6.16

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Vasogin(VAS.TO)

Jan 07, 2005
Have been building up their balance sheet to complete their final trials. Are now approaching a critical time. Feels the company can start to look better from here.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$6.45

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Vasogin(VAS.TO)

Sep 08, 2004
Top Short Doesn't feel they have a lot of R&D to show. Have a lot of cash on the books.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$6.50

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Vasogin(VAS.TO)

Mar 24, 2004
Interesting technology.
Photo of Ed HoEd Ho
No
Unlock Rating
$7.60

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Vasogin(VAS.TO)

Jan 23, 2004
Have signed on with a bigger company and now have to wait for the revenues and earnings to kick in. Easy money has been made.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$8.98

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Vasogin(VAS.TO)

Nov 20, 2003
Have no earnings and won’t for the next 3 years. Model price is $1.50.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$6.75

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Vasogin(VAS.TO)

Sep 26, 2003
Prefers companies with consistent earnings. Too speculative for them.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$7.98

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Vasogin(VAS.TO)

May 12, 2003
Looks like some one is accumulating it. Well run. A little expensive now.
Photo of Peter HodsonPeter HodsonUnlock Rating
$5.80

Stock price when the opinion was issued

biotechnologypharmaceutical
STRONG BUY

Vasogin(VAS.TO)

Apr 10, 2003
Bullish on the stock. 2 trials are in phase 3. Good cash position.
Photo of Robert FloydRobert FloydUnlock Rating
$4.80

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Vasogin(VAS.TO)

Apr 01, 2003
Interesting technology. Sector is doing well. Speculative.
Photo of David BurrowsDavid BurrowsUnlock Rating
$3.95

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Vasogin(VAS.TO)

Mar 03, 2003
Looking at a number of phase 3 trials. Good management.
Photo of Robert FloydRobert FloydUnlock Rating
$4.23

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Vasogin(VAS.TO)

Oct 10, 2002
They have done what they said they would.
Photo of Robert FloydRobert FloydUnlock Rating
$2.80

Stock price when the opinion was issued

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AEM.TO -17.72$228.02
COST -0.48$971.87
JPM 1.48$312.37
TOU.TO -1.69$63.73
SHOP.TO -8.75$152.79

Today's Top Picks

CSU.TO 67.76$2969.32
NFLX 0.62$82.18
LLY 6.15$1131.42
EVR -7.36$339.43
MSFT -11.38$416.67

Popular Articles

Latest Sell Signals

GSY.TO 0.43$40.53
CSCO -8.36$121.64
LULU -10.69$114.23
SES.TO -0.19$21.33
GFL.TO -0.26$49.51

Most Recent Experts

Brian Madden

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica